ACR on Air Clinical Challenges in ANCA Associated Vasculitis
Nov 5, 2024
Dr. Tanaz Kermani, founder of the Vasculitis Program at UCLA, dives into the complexities of ANCA-associated vasculitis. She discusses when to choose rituximab over cyclophosphamide and the potential of avacopan as an adjunct therapy. The conversation covers critical decision-making in steroid tapering and the viability of plasma exchange. Kermani also highlights the significance of accurate diagnosis through biopsies, emphasizing the role of pathologists in managing this rare autoimmune disorder.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Intro
00:00 • 2min
Navigating the Challenges of Vasculitis Diagnosis
01:52 • 3min
Interpreting Serologies in Vasculitis Diagnosis
04:31 • 2min
Navigating ANCA-Associated Vasculitis Management
06:44 • 15min
Pursuing a Career in Vasculitis: Guidance for Trainees
21:36 • 2min
Challenges in Diagnosing and Managing ANCA-Associated Vasculitis
23:23 • 3min